Clinical Trials Browser

Phase 4 × INDUSTRY × Lymphoma, B-Cell × Clear all

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma